Lexeo Therapeutics, Inc. Common Stock
NASDAQ: LXEO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- R. Nolan Townsend
- Employees
- 75
- Headquarters
- New York City, United States
- IPO year
- 2023
- Market cap
- $384.0M
- Website
- https://www.lexeotx.com
Loading LXEO…
Loading profile data…Frequently asked questions about LXEO
What does Lexeo Therapeutics, Inc. Common Stock (LXEO) do?
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA);...
Where does LXEO trade?
Lexeo Therapeutics, Inc. Common Stock (LXEO) trades on the NASDAQ Global Market.
What sector is LXEO in?
Lexeo Therapeutics, Inc. Common Stock (LXEO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lexeo Therapeutics, Inc. Common Stock?
R. Nolan Townsend is the chief executive officer of Lexeo Therapeutics, Inc. Common Stock (LXEO).
Where is Lexeo Therapeutics, Inc. Common Stock headquartered?
Lexeo Therapeutics, Inc. Common Stock is headquartered in United States.
Does LXEO pay a dividend?
Lexeo Therapeutics, Inc. Common Stock (LXEO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LXEO go public?
Lexeo Therapeutics, Inc. Common Stock (LXEO) completed its initial public offering in 2023.